Startups

Scientist, Mass Spectrometry

Axiom Bio · South San Francisco · On-site

← All jobs
About Axiom Bio

Axiom provides frontier intelligence for human drug toxicity, helping scientists reduce unexpected toxicity earlier and develop safer medicines with less animal testing. Backed by Amplify Partners.

About the role

Own Axiom’s LC-MS/MS operations across targeted and untargeted workflows, including chromatography, UV detection, mass spectrometry, and supporting equipment. Develop and run reactive-metabolism assays to identify drug metabolites and trapped reactive intermediates, using isotope-labeled controls to verify signals and support structural interpretation. Found on 1752vc Careers, the job board for startup and VC roles.

What they're looking for

  • LC-MS/MS operation and method development, including UHPLC, UV detection, high-resolution MS, and fragmentation methods
  • Instrument troubleshooting, preventive maintenance, vacuum systems, nitrogen generators, and sample preparation equipment
  • Reactive-metabolite trapping, metabolic incubations, stable-isotope labeling, and metabolite identification
  • Targeted and untargeted metabolomics, including extraction, chromatographic separation, and analysis of complex biological matrices
  • Proteomics sample preparation, protein digestion, peptide separation, and LC-MS/MS acquisition
  • Assay development and qualification, calibration, internal standards, matrix effects, recovery, carryover, and measurement uncertainty
More about this role

Build and run Axiom’s LC-MS/MS experiments to identify drug metabolites, measure changes in cellular metabolism and proteins, and uncover mechanisms of toxicity. Combine analytical expertise with robotics and scientific AI to generate reliable data and teach frontier models to predict human drug outcomes with insane accuracy.

Axiom’s mission is to eliminate unexpected drug toxicity and unlock an abundance of ultra safe medicines. We are starting with the liver, where toxicity remains a leading cause of drug failure. Our high-throughput human liver safety platform combines advanced human cell systems with imaging, transcriptomics, mass spectrometry, and drug metabolism measurements. Our AI agents integrate these data with chemical structure, human exposure, and thousands of clinical reference compounds to predict whether a drug will be toxic in humans, why, and how to make it safer.

We work with seven of the world’s top twenty pharmaceutical companies to design safety into molecules from the earliest stages. This applied work feeds directly into our partnerships with leading frontier AI labs, turning real discovery challenges and experimental feedback loops into scientific skill...

Read the full posting on Axiom Bio's site ↗

Build your edge while you search

Free tools for founders and investors, plus VC Unfiltered, our take on startups, venture and the people who build them.